A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

To join this study, adults must have multiple myeloma that has already been diagnosed and confirmed by doctors. Your myeloma treatments must have included certain types of drugs in the past, and your cancer needs to have come back or not responded to previous treatments. Importantly, your myeloma should show specific features, like a genetic change called t(11;14) or high levels of a protein called BCL2. You also shouldn't have been treated with a BCL-2 inhibitor medicine before.

There are also some reasons why people might not be able to join. For example, if you've had major surgery recently or are planning one soon, or if you have an active infection that hasn't cleared up before the study starts. The doctors running the study will carefully check all these details to make sure the study is right for you and safe.

If you decide to take part in this study, you will have regular visits to an approved hospital or clinic. These visits are important for the doctors to monitor your health, give you the study medication, and check for any side effects. You'll likely have blood tests and other medical assessments frequently to see how the treatment is affecting you and your myeloma.

The study medication, surzetoclax, is given as a tablet you swallow. Other medicines in the study might be given as an injection under the skin or also as tablets. The total time you would be in the study is about four and a half years, including both treatment and follow-up periods. This might mean more appointments than you would usually have with your standard care.